Gene-Based Interventions for Myocilin-Associated Glaucoma: August 2026 First-in-Human Learnings

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/gene-based-interventions-for-myocilin-associated-glaucoma-august-2026-first-in-human-learningsTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Gene-Based Interventions for Myocilin-Associated Glaucoma: August 2026 First-in-Human Learnings Evidence reviewed through August 24, 2026 Introduction Gene-based treatment for myocilin-associated glaucoma has moved from laboratory research into early human testing. The leading approach, called BD113, uses a virus-like particle to deliver a preassembled gene-editing system into the eye. Its goal is to disrupt the harmful form of the MYOC gene in the trabecular meshwork—the drainage tissue responsible for removing fluid from the eye. The early news is encouraging but extremely limited. A 2026 conference abstract reported sustained intraocular pressure reduction in one first-in-human participant without reported ocular or immune adverse events. A separate 2026 scientific review referred to two treated patients with normalized pressure and discontinuation of pressure-lowering medications. However, the full patient-level data—including exact pressure readings, duration of follow-up, visual-field results, editing measurements, and statistical analysis—have not been publicly reported. APAO 2026 abstract book Theranostics review () This distinction matters: a promising first human signal is not the same as proof of safety or effectiveness. As of August 24, 2026, the official ClinicalTrials.gov record still shows no posted study results and lists the trial’s status as unknown, although its last known status was recruiting. The original estimated study-completion date was December 2025. ClinicalTrials.gov: NCT06465537 () Why MYOC Is an Attractive Gene-therapy Target The MYOC gene provides instructions for making myocilin, a protein found in the trabecular meshwork and other eye tissues. Certain harmful MYOC variants cause the protein to fold incorrectly. The abnormal protein can accumulate inside trabecular meshwork cells, trigger stress in the endoplasmic reticulum, damage the cells, and reduce aqueous-fluid drainage. The result is often high intraocular pressure and progressive optic-nerve damage. Myocilin misfolding and glaucoma: a 20-year update CRISPR-Cas9-based treatment of myocilin-associated glaucoma () MYOC-related glaucoma is commonly inherited in an autosomal dominant pattern. It can cause juvenile-onset open-angle glaucoma, often with very high pressure at a young age, or adult-onset primary open-angle glaucoma. MYOC variants are estimated to account for approximately 3% to 4% of primary open-angle glaucoma and around 10% of juvenile-onset open-angle glaucoma, although the percentage varies among populations and study groups. MedlinePlus Genetics: MYOC APAO 2026 abstract book () The therapeutic logic is unusual. Many gene therapies replace a missing or defective gene. In MYOC-associated glaucoma, the proposed treatment instead aims to remove or silence a toxic, overactive gene product. Laboratory and animal studies support this strategy: disrupting mutant MYOC reduced abnormal protein accumulation, eased cellular stress, improved fluid outflow, lowered pressure, and preserved retinal ganglion cells in mouse models. CRISPR-Cas9-based treatment of myocilin-associated glaucoma () What Was Reported in Humans by August 2026? BD113: The Directly MYOC-Targeted Program BD113 is described in the clinical registry as an integration-defective lentiviral-derived virus-like particle carrying a guide ribonucleic acid and CRISPR-associated protein 9 as a preassembled ribonucleoprotein complex. The intended effect is to knock out or substantially reduce the harmful MYOC gene activity in trabecular meshwork cells. ClinicalTrials.gov: NCT06465537 () The public human evidence can be summarized as follows: For the full table, please open this article on visualfieldtest.com. The most important limitation is that the public reports do not provide the information needed to judge treatment magnitude. The available material does not specify the patient’s starting pressure, lowest pressure, pressure without medication, length of follow-up, number of glaucoma medicines before treatment, visual-field status, or whether the treatment prevented progression. The review’s reference to two patients also differs from the conference abstract’s reference to one patient. This may reflect later enrollment or reporting, but that is an inference rather than a confirmed final dataset. APAO 2026 abstract book Theranostics review () What Is Known About the Trial Design? The registered study planned to enroll approximately 6 to 9 adults at Beijing Tongren Hospital in China. Participants were divided into two broad groups: People with a study eye that had little or no useful vision, intended to provide an additional safety margin. People with useful vision in the study eye and a blood-confirmed MYOC mutation. Each participant was scheduled to receive one intracameral injection in the study eye. The planned follow-up was at least one year. ClinicalTrials.gov: NCT06465537 () The main planned pressure outcomes were: The proportion of participants with intraocular pressure of 21 millimeters of mercury or less. The proportion with at least a 20% pressure reduction from baseline. Ocular adverse events such as inflammation, bleeding, infection, corneal reaction, or damage to the anterior segment. In participants with useful vision, changes in visual acuity, visual fields, and retinal nerve-fiber-layer measurements. The threshold of 21 millimeters of mercury is a trial measurement, not a universal treatment goal. A safe target pressure depends on the amount of optic-nerve damage, the rate of progression, corneal thickness, age, and other factors. Delivery Route and Dose Intracameral Delivery BD113 is injected into the anterior chamber, the fluid-filled space between the cornea and iris. This is different from an intravitreal injection, which is placed farther back in the eye near the retina. The intracameral route is intended to expose the anterior segment and trabecular meshwork directly. In mouse experiments, the virus-like particle reportedly showed more selective delivery to the trabecular meshwork than conventional adeno-associated virus or lipid nanoparticles, which showed more dispersion toward the cornea. APAO 2026 abstract book () An intracameral injection is a familiar type of eye procedure, but it is not risk-free. Possible complications include: Temporary or persistent inflammation Bleeding in the anterior chamber Infection Corneal endothelial injury Pressure spikes or pressure that becomes too low Damage related to the injection itself The study registry specifically lists endophthalmitis, hypopyon, hyphema, and corneal injection-site reactions among the adverse events being monitored. ClinicalTrials.gov: NCT06465537 () Single Dose of 4 Micrograms of p24 Protein Equivalent The registered BD113 dose is 4 micrograms of p24 protein equivalent in a single intracameral injection. The p24 measurement reflects a viral-particle manufacturing and quantity assay. It is not directly equivalent to the amount of CRISPR-associated protein 9, the number of guide molecules, or the amount of conventional viral-vector genomes. ClinicalTrials.gov: NCT06465537 () The publicly available trial information does not describe a conventional multi-level dose-escalation table for BD113. Therefore, it is not yet possible to determine whether the reported pressure effect is dose-related or whether a lower dose might provide a better safety margin. Target Engagement: What Has and Has Not Been Shown? Target engagement means evidence that the treatment reached and changed the intended biological target. For a MYOC-editing treatment, the strongest evidence would include: Editing of the MYOC gene in treated trabecular meshwork cells. Lower levels of abnormal myocilin protein. Reduced endoplasmic-reticulum stress. Improved aqueous-fluid outflow. Lower intraocular pressure. Slower structural or functional glaucoma progression. Animal Evidence The BD113 abstract reported approximately 35% editing in cynomolgus macaques, even though the animals had pre-existing immunity against CRISPR-associated protein 9. This is important because it suggests that pre-existing immune recognition does not necessarily prevent editing. However, the result was reported in a conference abstract and does not substitute for human tissue evidence. APAO 2026 abstract book () Other recent preclinical approaches have produced measurable target engagement: A messenger-ribonucleic-acid lipid-polymer system produced approximately 18% MYOC editing in a mouse study, reduced abnormal protein accumulation, and lowered pressure within several weeks. No obvious ocular inflammation was seen during the reported observation period. PubMed: therapeutic messenger-ribonucleic-acid delivery of CRISPR-associated protein 9 () A 2026 lipid-nanoparticle base-editing study reported approximately 17% editing, approximately 46% lower mutant myocilin protein, reduced cellular stress, and rescue of the glaucoma phenotype in mice, without detected ocular toxicity or off-target editing in the reported experiments. PubMed: lipid-nanoparticle-mediated base editing () Human Target Engagement Remains Unconfirmed The BD113 clinical registry plans to measure p24 and CRISPR-associated proteiSupport the show